Roth Capital Partners News
-
ICU Medical Inc., the maker of intravenous medical equipment that surged to a record this week after Bloomberg News said it’s considering a sale, could fetch 21 percent more in a takeover.
-
SodaStream International Ltd., the Israeli home soda-machine maker that has returned five times the Nasdaq Composite Index in the past year, is rising on speculation the company will beat its own revenue forecast.
-
ClickSoftware Technologies Ltd., the Israeli maker of workplace software, is rebounding from a five-month low after reiterating sales will rise as much as 25 percent as businesses boost spending on phone applications.
-
Pandora Media Inc., grappling with rising music costs, expects the royalties it pays to artists and record labels to decline to 40 percent of revenue from about 60 percent now, Chief Financial Officer Mike Herring said.
-
New Oriental Education & Technology Group Inc. rose the most since July in New York as a buyout offer for Chinese tutoring firm Ambow Education Holding Ltd. fueled speculation the bigger company may also be targeted.
-
Muddy Waters LLC, whose analyst reports triggered $7 billion in losses for Chinese stocks, used an unlikely secret weapon for its research: the public website of the U.S. Securities and Exchange Commission.
-
Regeneron Pharmaceuticals Inc. reported a successful study result in its new drug for treating gout, the first of three new treatments that may generate at least $2 billion a year in revenue.
-
Focus Media Holding Ltd., a Chinese advertising company, agreed to be bought by a consortium of investors led by Carlyle Group LP in a $3.7 billion deal that will be the country’s largest leveraged buyout.
-
Chinese equities in New York climbed to a seven-month high after the World Bank boosted China’s 2013 economic growth forecast. Focus Media Holding Ltd. jumped after agreeing to go private in China’s biggest leveraged buyout.
-
Dendreon Corp. won approval for its only product, the prostate cancer vaccine Provenge, concluding a three-year battle with U.S. regulators to introduce the first therapy to train the body’s immune system to destroy tumors.
|
|
Most Popular on Bloomberg
|
|
Roth Capital Partners Videos
|
|
Rate this Page